InCephalo AG, based in Switzerland, is a preclinical biotechnology company founded in 2021 by leading experts in the field of brain cancer. The company leverages its proprietary technology platform to develop compartment-locked (C-Locked) therapies that are tailor-made for local applications for brain cancer. InCephalo’s platform aims to deliver therapies to offer better response rates, more prolonged survival and improved quality of life to patients with brain cancer.
The currently obtained grant is financed by the Swiss State Secretariat for Education, Research and Innovation (SERI). This funding is part of the transitional measures for Horizon Europe, as Switzerland is currently treated as a non-associated third country in the EU Framework Programme for Research and Innovation. The start-up would not have been able to overcome the hurdles of the non-association of Swiss companies to the Horizon programmes without the EIT Health Gold Track.
“InCephalo graduated from the Gold Track programme in June 2022 and was awarded within our Grant-for-Option model. They clearly demonstrated the significant and outstanding progress made over the last 12 months, consolidating their potential to massively scale globally. We are honoured to contribute and participate in their future success via this grant,” says Dr. Kurt Höller, Director of Business Creation at EIT Health.
“We are excited to receive this award as it further validates our technology platform and allows us to widen our pipeline,” says Dr Carlo Bertozzi, CEO and co-founder of InCephalo.